Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.39 Insider Own50.71% Shs Outstand248.92M Perf Week-7.09%
Market Cap326.09M Forward P/E- EPS next Y-0.27 Insider Trans0.00% Shs Float122.70M Perf Month-5.76%
Income-95.90M PEG- EPS next Q-0.09 Inst Own30.79% Short Float13.77% Perf Quarter0.77%
Sales6.22M P/S52.43 EPS this Y13.85% Inst Trans-6.87% Short Ratio16.47 Perf Half Y11.97%
Book/sh0.48 P/B2.75 EPS next Y20.83% ROA-49.78% Short Interest16.90M Perf Year12.93%
Cash/sh0.25 P/C5.19 EPS next 5Y2.40% ROE-78.37% 52W Range0.84 - 1.88 Perf YTD-2.24%
Dividend Est.- P/FCF- EPS past 5Y36.94% ROI-77.10% 52W High-30.32% Beta1.76
Dividend TTM- Quick Ratio2.99 Sales past 5Y-20.14% Gross Margin-58.32% 52W Low56.81% ATR (14)0.08
Dividend Ex-Date- Current Ratio2.99 EPS Y/Y TTM-20.13% Oper. Margin-1428.50% RSI (14)37.70 Volatility5.45% 5.24%
Employees202 Debt/Eq0.06 Sales Y/Y TTM-88.35% Profit Margin-1540.63% Recom1.80 Target Price9.00
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q-24.69% Payout- Rel Volume0.79 Prev Close1.36
Sales Surprise-42.47% EPS Surprise-64.56% Sales Q/Q-30.35% EarningsMar 19 AMC Avg Volume1.03M Price1.31
SMA20-7.58% SMA50-10.43% SMA200-2.54% Trades Volume810,880 Change-3.68%
Date Action Analyst Rating Change Price Target Change
Mar-22-24Downgrade JP Morgan Neutral → Underweight
May-23-23Initiated JP Morgan Neutral
Nov-18-22Initiated Cantor Fitzgerald Overweight $7
Feb-25-21Initiated Stifel Buy $13
Feb-22-21Initiated Wells Fargo Overweight $14
Feb-18-21Initiated B. Riley Securities Buy $10
May-08-20Initiated H.C. Wainwright Buy $5
Mar-28-24 04:05PM
Mar-27-24 08:20AM
Mar-20-24 10:07AM
Mar-19-24 08:53PM
04:05PM Loading…
Mar-12-24 04:05PM
Mar-05-24 04:05PM
Feb-06-24 04:05PM
Jan-16-24 08:05AM
Jan-08-24 08:30AM
Jan-02-24 12:40PM
Dec-18-23 04:05PM
Nov-29-23 04:05PM
Nov-09-23 04:55PM
04:05PM Loading…
Nov-07-23 04:05PM
Sep-19-23 04:05PM
Aug-09-23 08:00AM
Aug-03-23 04:05PM
Jun-20-23 07:30AM
Jun-05-23 04:05PM
Jun-03-23 12:00PM
May-31-23 08:05AM
May-10-23 08:00AM
May-03-23 08:30AM
Apr-26-23 04:05PM
Apr-17-23 09:01AM
Apr-03-23 04:30PM
Mar-29-23 08:05AM
08:05AM Loading…
Mar-28-23 08:05AM
Mar-06-23 04:05PM
Feb-07-23 08:00AM
Jan-30-23 02:34PM
Jan-27-23 04:05PM
Jan-24-23 10:40PM
Jan-11-23 06:45PM
Jan-04-23 04:05PM
Dec-27-22 08:00AM
Dec-19-22 04:05PM
Dec-12-22 07:01PM
Nov-16-22 05:07AM
Nov-09-22 04:05PM
Nov-02-22 04:30PM
Sep-21-22 04:30PM
Sep-01-22 08:05AM
Aug-22-22 08:05AM
Aug-08-22 04:05PM
Aug-05-22 08:36AM
Aug-01-22 04:05PM
Jul-06-22 08:09AM
Jul-05-22 08:05AM
Jun-27-22 04:05PM
May-17-22 04:05PM
May-14-22 08:15AM
May-11-22 06:29AM
May-09-22 04:05PM
May-02-22 03:00PM
Apr-04-22 08:05AM
Apr-03-22 03:40PM
Mar-01-22 08:00AM
Feb-02-22 10:10AM
Feb-01-22 09:38PM
Jan-24-22 02:48PM
Jan-12-22 04:30PM
Jan-11-22 10:00AM
Jan-05-22 04:05PM
Dec-13-21 05:05PM
Dec-01-21 07:56AM
Nov-24-21 08:38AM
Nov-10-21 04:05PM
Nov-04-21 09:15AM
Nov-01-21 03:01PM
Oct-27-21 04:38PM
Oct-26-21 08:05AM
Oct-12-21 08:05AM
Oct-05-21 05:00AM
Oct-04-21 08:34AM
Oct-01-21 08:05AM
Sep-21-21 10:55AM
Sep-01-21 08:05AM
Aug-09-21 04:01PM
Aug-02-21 04:05PM
Jun-23-21 05:12AM
Jun-10-21 05:05PM
May-10-21 04:30PM
Apr-28-21 12:33PM
Mar-30-21 04:05PM
Mar-25-21 05:46AM
Mar-23-21 08:05AM
Mar-18-21 08:30AM
Mar-01-21 04:05PM
Feb-22-21 04:05PM
Feb-04-21 04:05PM
Jan-26-21 04:05PM
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIRK RANDAL JDirectorMar 09 '24Option Exercise0.00213,675032,051,461Mar 12 05:36 PM
KIRK RANDAL JDirectorDec 28 '23Buy1.4196,686136,3271,096,686Dec 29 07:30 PM
KINDLER JEFFREY BDirectorDec 28 '23Sale1.4196,686136,327238,275Dec 29 07:19 PM
MITCHELL DEAN JDirectorSep 22 '23Buy1.4125,00035,250356,836Sep 25 04:02 PM
Sabzevari HelenPresident and CEOAug 25 '23Sale1.5376,969117,7631,560,004Aug 25 07:04 PM
Lehr Donald P.Chief Legal OfficerAug 24 '23Sale1.6410,94717,953428,916Aug 25 07:03 PM
Thomasian Harry Jr.Chief Financial OfficerAug 24 '23Sale1.649,04514,834161,051Aug 25 06:59 PM
Perez Jeffrey ThomasSVP, IP AffairsAug 24 '23Sale1.648,89114,581458,903Aug 25 07:00 PM
Shah Rutul RChief Operating OfficerAug 24 '23Sale1.645,3888,836133,474Aug 25 07:01 PM
Sabzevari HelenPresident and CEOAug 18 '23Sale1.6655,85592,7191,495,386Aug 18 09:06 PM
Lehr Donald P.Chief Legal OfficerAug 17 '23Sale1.5510,76216,681418,153Aug 18 09:13 PM
Thomasian Harry Jr.Chief Financial OfficerAug 17 '23Sale1.558,89313,784152,162Aug 18 09:15 PM
Perez Jeffrey ThomasSVP, IP AffairsAug 17 '23Sale1.558,74113,549448,916Aug 18 09:18 PM
Shah Rutul RChief Operating OfficerAug 17 '23Sale1.555,2988,212123,382Aug 18 09:09 PM
KIRK RANDAL JDirectorAug 16 '23Buy1.51119,411180,31131,837,786Aug 17 08:19 AM
KIRK RANDAL JDirectorAug 15 '23Buy1.52380,589577,30131,718,375Aug 17 08:19 AM
Hassan FredDirectorAug 14 '23Buy1.75570,345998,104878,942Aug 16 04:31 PM
Frank StevenDirectorAug 14 '23Buy1.72400,000688,000882,358Aug 15 04:18 PM
Sabzevari HelenPresident and CEOAug 11 '23Sale1.4441,43659,6681,409,654Aug 11 07:24 PM
Lehr Donald P.Chief Legal OfficerAug 10 '23Sale1.2111,02613,341407,205Aug 11 07:28 PM
Perez Jeffrey ThomasSVP, IP AffairsAug 10 '23Sale1.218,95610,837438,779Aug 11 07:26 PM
Thomasian Harry Jr.Chief Financial OfficerAug 10 '23Sale1.216,8528,291143,121Aug 11 07:27 PM
Shah Rutul RChief Operating OfficerAug 10 '23Sale1.215,4296,569113,200Aug 11 07:29 PM
Sabzevari HelenPresident and CEOAug 04 '23Sale1.1052,87058,1571,309,503Aug 04 07:05 PM
Lehr Donald P.Chief Legal OfficerAug 03 '23Sale1.2010,82112,985396,521Aug 04 07:09 PM
Perez Jeffrey ThomasSVP, IP AffairsAug 03 '23Sale1.208,78910,547428,857Aug 04 07:10 PM
Thomasian Harry Jr.Chief Financial OfficerAug 03 '23Sale1.206,7248,069132,039Aug 04 07:08 PM
Shah Rutul RChief Operating OfficerAug 03 '23Sale1.205,3286,394103,149Aug 04 07:06 PM